Socioeconomic aspects of implantable devices: can we afford new technology?
Author:
Steinbach Konrad K.
Publisher
Springer Netherlands
Reference17 articles.
1. Akhtar M, Avitall B, Jazayeri M et al. Role of implantable cardioverter defibrillator therapy in the management of high risk patients. Circulation 1992; 85(Suppl I): 131–139.
2. Farrell TG, Bashir Y, Cripps T. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18: 687–697.
3. Klein H, Trappe HJ, Fiegeth HG, Nisam S. Prospective studies evaluating prophylactic ICD therapy for high risk patients with coronary artery disease. PACE 1993; 16: 564–570.
4. Brugada P, Andries E. The rationale for prophylactic implantation of a defibrillator in ‘high risk’ patients. PACE 1993; 16: 547–551.
5. Hauer RNW, Wever EFD, Crijns HJGM. Automatic implantable cardioverter defibrillator: Cost effectiveness. PACE 1993; 16: 559–563.